Defining a therapeutic window for the novel <scp>TGF</scp>‐β inhibitor <scp>LY</scp>2157299 monohydrate based on a pharmacokinetic/pharmacodynamic model

Abstract

A therapeutic window for the clinical investigation of LY2157299 in cancer patients was defined using a targeted PK/PD approach, which integrated translational biomarkers and preclinical toxicity. The study supports using a therapeutic window based on a PK/PD model in early oncology development.